Arcellx Announces Its Participation at TD Cowen's 6th Annual Oncology Innovation Summit and Its Investor Event During EHA2025
REDWOOD CITY, Calif., May 21, 2025--(BUSINESS WIRE)--Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today announced two upcoming investor events:
TD Cowen's 6th Annual Oncology Innovation SummitTuesday, May 27, 2025 at 9:00 a.m. PT (Virtual)
Management and Physician Presentation and Discussion of iMMagine-1 Pivotal Study Results During EHA2025Friday, June 13, 2025 at 8:30 p.m. CEST (Virtual and In-Person, Milan, Italy)
A live webcast of these discussions will be accessible from Arcellx's website at www.arcellx.com in the Investors section. A replay of the webcasts will be archived and available for 30 days following the event.
About Arcellx, Inc.
Arcellx, Inc. is a clinical-stage biotechnology company reimagining cell therapy by engineering innovative immunotherapies for patients with cancer and other incurable diseases. Arcellx believes that cell therapies are one of the forward pillars of medicine and Arcellx's mission is to advance humanity by developing cell therapies that are safer, more effective, and more broadly accessible. For more information on Arcellx, please visit www.arcellx.com. Follow Arcellx on X @arcellx and LinkedIn.
Forward-looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements in this press release that are not purely historical are forward-looking statements, including Arcellx's expectations regarding the timing and outcomes of clinical trials for its product candidates and the potential impact of its product candidates and platforms on patients and cell therapy. The forward-looking statements contained herein are based upon Arcellx's current expectations and involve assumptions that may never materialize or may prove to be incorrect. These forward-looking statements are neither promises nor guarantees and are subject to a variety of risks and uncertainties, including risks that may be found in the section entitled "Part II, Item 1A (Risk Factors) in the Quarterly Report on Form 10-Q for the quarter ended March 31, 2025, filed with the Securities and Exchange Commission (SEC) on May 8, 2025, and other documents that Arcellx files from time to time with the SEC. These forward-looking statements are made as of the date of this press release, and Arcellx assumes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250521064521/en/
Contacts
Investors: Myesha Lacyir@arcellx.com 510-418-2412
Media: Andrea CohenSam Brown LLCandreacohen@sambrown.com 917-209-7163
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Insider
28 minutes ago
- Business Insider
The Week That Was, The Week Ahead: Macro & Markets, June 8, 2025
Everything to Know about Macro and Markets Stocks clocked in large weekly gains, returning to positive territory year-to-date. The Dow Jones Industrial Average (DJIA) rose by 1.17%, the S&P 500 (SPX) increased by 1.50%, and the tech-heavy Nasdaq-100 (NDX) gained 1.97% for the week. The S&P 500 finished more than 20% above April's low, reclaiming the 6,000 mark first reached in February, although it remained about 2% shy of its record high. Confident Investing Starts Here: Macro Steers the Markets The week began on a positive note, losing some steam in the second half. The weakness in PMI reports – with the manufacturing activity contracting for a third month in a row and services activity shrinking for the first time in 11 months – infused some gloom. However, Friday saw stocks find their footing again on solid job gains, which allayed fears about an imminent economic downturn. U.S. jobs growth stayed strong in May, climbing 139,000 with unemployment unchanged at 4.2%. Although the March and April reports were revised downward, May's report reassured investors, as it reflected a very gradual cooling of the labor market. Still, diving into the job report's details, a stronger-than-expected wage growth continues to put a floor under inflation. This supports the Federal Reserve's 'wait and see' stance, despite President Trump's demands for a cut. According to the CME FedWatch Tool, the chances of a June cut are nil, and July's rate decrease looks increasingly improbable. Prices in interest rate futures markets imply that investors expect two quarter-point rate cuts by year-end, with the first cut not expected until September. Wrapping Up the Season Despite tariff headwinds and macro volatility, S&P 500 companies delivered solid results last quarter. Index members reported 12.9% year-over-year earnings growth – the second straight double-digit increase. 78% of firms – above the five-year average – exceeded EPS estimates. However, the number of companies issuing negative EPS guidance (68) was also above the average. In Q1, the Healthcare sector reported the highest earnings growth, 43%, leaving the Magnificent Seven cohort's 27.7% increase in the dust. In fact, Mag 7's earnings growth rate was below the average (32.1%) of the previous three quarters. Still, three members of the Magnificent bunch – Alphabet (GOOGL), Amazon (AMZN), and Nvidia (NVDA) – are among the top five contributors to earnings growth for the S&P 500 for the first quarter. Interestingly, Bristol Myers Squibb (BMY) and Gilead Sciences (GILD) were the other top contributors. Stocks That Made the News ▣ Tesla (TSLA) lost nearly 15% over the week following the ugly social media spat between Elon Musk and President Donald Trump. The feud flared up over the impending budget bill, with Musk calling it 'disgusting', and followed by Trump's threat to take away billions of dollars in government subsidies and contracts awarded to Musk's businesses. Although shares rebounded on Friday as Musk and Trump moved to cool tensions, the spat cost Tesla over $150 billion loss in market cap. ▣ Broadcom (AVGO) fell on Friday, wiping out its weekly gain, after the chip giant only narrowly surpassed analyst revenue and expectations. In addition, its current quarter revenue guidance was also just above consensus. Solid, but not a blowout quarter and outlook, weighed on shares that recently hit all-time highs. Still, the company delivered on the AI narrative, reporting surging demand and upping AI networking revenue guidance. ▣ Microsoft (MSFT) continued its climb, hitting a fresh record on Friday as analysts raised price targets on acceleration in Azure and AI-related revenue growth. According to Goldman Sachs, Microsoft's cloud revenue could more than double by 2029. The tech leader's market cap has reached $3.5 trillion, surpassing that of Nvidia (NVDA) and making MSFT the largest company in the world. ▣ Lululemon (LULU) shares dove by 20% on Friday, capping large weekly losses, despite earnings beat. The apparel retailer cut guidance on macroeconomic uncertainty and the impact of tariffs that might force LULU to increase prices. ▣ DocuSign (DOCU) was another notable decliner, sinking nearly 19% post earnings. The company reported a strong financial performance, but a miss on billings raised investor fears about future growth. The Q1 2025 earnings season is practically over, but several notable earnings releases are still scheduled for the next few days. These include Casey's General (CASY), Oracle (ORCL), Chewy (CHWY), and Adobe (ADBE).
Yahoo
30 minutes ago
- Yahoo
Why Quantum Computing Inc. (QUBT) Soared On Friday
We recently published a list of . In this article, we are going to take a look at where Quantum Computing Inc. (NASDAQ:QUBT) stands against other Friday's best-performing stocks. Quantum Computing surged by 15.81 percent on Friday to end at $13.70 apiece as investors cheered the company's upgraded rating from an investment firm. In its market note, Ascendiant Capital Markets maintained its 'buy' recommendation on Quantum Computing Inc.'s (NASDAQ:QUBT) stock, while raising its price target to $22 from $14 previously. A data analyst pouring over a chart, the intricacies of its lines being revealed. The new price target represented a 60.6 percent upside from the company's latest closing price. In the first quarter of the year, Quantum Computing Inc. (NASDAQ:QUBT) swung to a net income attributable to shareholders of $16.98 million from a $6.4 million net loss in the same period last year, primarily driven by a $23.6 million non-cash gain on the mark-to-market valuation of the company's warrant liability as a result of its merger with QPhoton in June 2022. Revenues, on the other hand, rose by 44 percent to $39,000 from $27,000 in the same period last year. Overall, QUBTranks 3rd on our list of Friday's best-performing stocks. While we acknowledge the potential of QUBT as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock. READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires. Disclosure: None. This article is originally published at Insider Monkey.
USA Today
36 minutes ago
- USA Today
Notre Dame AD Pete Bevacqua to discuss college athletics with President Trump
Notre Dame AD Pete Bevacqua to discuss college athletics with President Trump Notre Dame athletic director Pete Bevacqua and SEC commissioner Greg Sankey are reportedly meeting with President Donald Trump Sunday to discuss the future of college athletics. According to Ross Dellenger of Yahoo! Sports, Bevacqua and Sankey are traveling to Trump National Golf Club in Bedminster to have a round with the 47th President, who is interested in discussing the college sports industry's future while on the course. This reported meeting comes at a time when the state of college athletics has never been more in flux. The House vs. NCAA settlement was finally finalized this past Friday evening, clearing a path for future revenue-sharing payments to be made directly to student-athletes for the very first time, further professionalizing college athletics. It allows for the establishment of an NIL Go Clearinghouse, which would have to approve NIL payments of more than $600 to student-athletes beginning this summer. Trump's interest in college athletics is nothing new. Previously he was working on a college sports commission that reportedly was going to be co-chaired by former Alabama head coach Nick Saban. Certainly there is never a dull day in the business of college athletics. Contact/Follow us @IrishWireND on X (Formerly Twitter), and like our page on Facebook to follow ongoing coverage of Notre Dame news, notes, and opinions. Follow Dave on X: Miller_Dave
